Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Janux Therapeutics, Inc. | janx-20210630ex31_2.htm |
| EX-31.1 - EX-31.1 - Janux Therapeutics, Inc. | janx-20210630ex31_1.htm |
| 10-Q - 10-Q - Janux Therapeutics, Inc. | janx-20210630.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Janux Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: August 10, 2021 |
|
By: |
/s/ David Campbell |
|
|
|
David Campbell, Ph.D. |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
Date: August 10, 2021 |
|
By: |
/s/ Tighe Reardon |
|
|
|
Tighe Reardon |
|
|
|
Acting Chief Financial Officer (Principal Financial and Accounting Officer) |